Dermira (DERM) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Dermira (DERM) Tops Q3 EPS by 5c

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

November 12, 2024 4:01 PM EST

U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025

Total revenues for the third quarter ended September 30, 2024 were $14.6 million

SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (Journey Medical or the Company, we, or our), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (FDA)-approved prescription pharmaceutical... More